In this Supplement
The latest thinking on DAPT guidelines and patient care.
A deficit of randomized PCI data including the high bleeding risk population makes it challenging to define the optimal management of these patients.
By Thomas Cuisset, MD
Less is more when treating high bleeding risk patients with latest-generation DESs and short DAPT duration.
By Michel Zeitouni, MD; and Gilles Montalescot, MD, PhD
By Kazushige Kadota, MD, PhD
Expert commentary on the roles of technology and pharmacology.
By Hiroyuki Jinnouchi, MD; Renu Virmani, MD; and Aloke V. Finn, MD
When anatomically complex meets clinically complex.